Neuropathy News and Research

RSS

$First drug approved for hormone refractory prostate cancer that has shown a survival benefit$

First drug approved for hormone refractory prostate cancer that has shown a survival benefit

The the Food and Drug Administration (FDA) approved Taxotere (docetaxel), injection in combination with prednisone ( a steroid), for the treatment of patients with advanced metastatic prostate cancer. This is the first drug approved for hormone refractory prostate cancer that has shown a survival benefit.

19 May 2004

Closer to understanding the function of a protein linked to an inherited form of the movement disorder dystonia

The protein, torsinA, is defective in patients with DYT1 dystonia, an inherited condition that causes uncontrollable movements in the limbs and torso. Learning what torsinA does could be an important step toward developing a treatment for the disorder.

19 May 2004

Studies show pregabalin does not affect male reproductivity or interfere with oral contraceptives

Two studies presented today at the American Academy of Neurology (AAN) 56th Annual Meeting show that pregabalin, when used as an add-on treatment for epilepsy, does not affect male reproductive function or interfere with the effectiveness of oral contraceptives.

29 Apr 2004

Risk Assessment of Diabetic Retiopathy Improved by Screening Methods

Eli Lilly and Company as part of a continued commitment to innovation in the area of diabetes, announced today the creation of a strategic relationship with EyeTel Imaging, Inc. to improve screening and detection of diabetic retinopathy, one of the potentially devastating diabetic microvascular complications. The agreement, which expands the relationship between the two companies, will provide EyeTel with on-going operational support from Lilly, allowing EyeTel to provide primary care physicians access to state-of-the-art patient risk assessment tools and education programs.

23 Mar 2004